50 related articles for article (PubMed ID: 30359003)
1. Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders.
Rageot D; Bohnacker T; Melone A; Langlois JB; Borsari C; Hillmann P; Sele AM; Beaufils F; Zvelebil M; Hebeisen P; Löscher W; Burke J; Fabbro D; Wymann MP
J Med Chem; 2018 Nov; 61(22):10084-10105. PubMed ID: 30359003
[TBL] [Abstract][Full Text] [Related]
2. The mTOR Independent Function of Tsc1 and FNIPs.
Sager RA; Woodford MR; Mollapour M
Trends Biochem Sci; 2018 Dec; 43(12):935-937. PubMed ID: 30361061
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal Effects of Everolimus on White Matter Diffusion in Tuberous Sclerosis Complex.
Peters JM; Prohl A; Kapur K; Nath A; Scherrer B; Clancy S; Prabhu SP; Sahin M; Franz DN; Warfield SK; Krueger DA
Pediatr Neurol; 2019 Jan; 90():24-30. PubMed ID: 30424962
[TBL] [Abstract][Full Text] [Related]
4. Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex.
Theilmann W; Gericke B; Schidlitzki A; Muneeb Anjum SM; Borsdorf S; Harries T; Roberds SL; Aguiar DJ; Brunner D; Leiser SC; Song D; Fabbro D; Hillmann P; Wymann MP; Löscher W
Neuropharmacology; 2020 Dec; 180():108297. PubMed ID: 32890589
[TBL] [Abstract][Full Text] [Related]
5. 4-(Difluoromethyl)-5-(4-((3
Borsari C; Keles E; Rageot D; Treyer A; Bohnacker T; Bissegger L; De Pascale M; Melone A; Sriramaratnam R; Beaufils F; Hamburger M; Hebeisen P; Löscher W; Fabbro D; Hillmann P; Wymann MP
J Med Chem; 2020 Nov; 63(22):13595-13617. PubMed ID: 33166139
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety.
Borsari C; Rageot D; Beaufils F; Bohnacker T; Keles E; Buslov I; Melone A; Sele AM; Hebeisen P; Fabbro D; Hillmann P; Wymann MP
ACS Med Chem Lett; 2019 Oct; 10(10):1473-1479. PubMed ID: 31620236
[TBL] [Abstract][Full Text] [Related]
7. Neolymphostin A Is a Covalent Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitor That Employs an Unusual Electrophilic Vinylogous Ester.
Castro-Falcón G; Seiler GS; Demir Ö; Rathinaswamy MK; Hamelin D; Hoffmann RM; Makowski SL; Letzel AC; Field SJ; Burke JE; Amaro RE; Hughes CC
J Med Chem; 2018 Dec; 61(23):10463-10472. PubMed ID: 30380865
[TBL] [Abstract][Full Text] [Related]
8. A mammalian protein targeted by G1-arresting rapamycin-receptor complex.
Brown EJ; Albers MW; Shin TB; Ichikawa K; Keith CT; Lane WS; Schreiber SL
Nature; 1994 Jun; 369(6483):756-8. PubMed ID: 8008069
[TBL] [Abstract][Full Text] [Related]
9. Sequential genome-wide CRISPR-Cas9 screens identify genes regulating cell-surface expression of tetraspanins.
Yang J; Guo F; Chin HS; Chen GB; Ang CH; Lin Q; Hong W; Fu NY
Cell Rep; 2023 Feb; 42(2):112065. PubMed ID: 36724073
[TBL] [Abstract][Full Text] [Related]
10. The
Ampudia-Mesias E; Cameron CS; Yoo E; Kelly M; Anderson SM; Manning R; Abrahante Lloréns JE; Moertel CL; Yim H; Odde DJ; Saydam N; Saydam O
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674001
[TBL] [Abstract][Full Text] [Related]
11. Identification of Promising Drug Candidates against Prostate Cancer through Computationally-Driven Drug Repurposing.
Bernal L; Pinzi L; Rastelli G
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834548
[TBL] [Abstract][Full Text] [Related]
12. Brain-restricted mTOR inhibition with binary pharmacology.
Zhang Z; Fan Q; Luo X; Lou K; Weiss WA; Shokat KM
Nature; 2022 Sep; 609(7928):822-828. PubMed ID: 36104566
[TBL] [Abstract][Full Text] [Related]
13. Two-drug trick to target the brain blocks toxicity in the body.
Wymann MP; Borsari C
Nature; 2022 Sep; 609(7928):681-683. PubMed ID: 36104488
[No Abstract] [Full Text] [Related]
14. Overview of Research into mTOR Inhibitors.
Mao B; Zhang Q; Ma L; Zhao DS; Zhao P; Yan P
Molecules; 2022 Aug; 27(16):. PubMed ID: 36014530
[TBL] [Abstract][Full Text] [Related]
15. DBU mediated one-pot synthesis of triazolo triazines
Ganai AM; Pathan TK; Sayyad N; Kushwaha B; Kushwaha ND; Tzakos AG; Karpoormath R
RSC Adv; 2022 Jan; 12(4):2102-2106. PubMed ID: 35425261
[TBL] [Abstract][Full Text] [Related]
16. Pd-Catalyzed Difluoromethylations of Aryl Boronic Acids, Halides, and Pseudohalides with ICF
Gedde OR; Bonde A; Golbaekdal PI; Skrydstrup T
Chemistry; 2022 Jun; 28(34):e202200997. PubMed ID: 35388933
[TBL] [Abstract][Full Text] [Related]
17. The Anti-Non-Small Cell Lung Cancer Cell Activity by a mTOR Kinase Inhibitor PQR620.
Zha JH; Xia YC; Ye CL; Hu Z; Zhang Q; Xiao H; Yu BT; Xu WH; Xu GQ
Front Oncol; 2021; 11():669518. PubMed ID: 34178653
[TBL] [Abstract][Full Text] [Related]
18. Chemical and Structural Strategies to Selectively Target mTOR Kinase.
Borsari C; De Pascale M; Wymann MP
ChemMedChem; 2021 Sep; 16(18):2744-2759. PubMed ID: 34114360
[TBL] [Abstract][Full Text] [Related]
19. Copper-catalyzed carbo-difluoromethylation of alkenes via radical relay.
Cai A; Yan W; Zeng X; Zacate SB; Chao TH; Krause JA; Cheng MJ; Liu W
Nat Commun; 2021 Jun; 12(1):3272. PubMed ID: 34075051
[TBL] [Abstract][Full Text] [Related]
20. Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood-brain barrier permeability.
Borsari C; Keles E; Treyer A; De Pascale M; Hebeisen P; Hamburger M; Wymann MP
RSC Med Chem; 2021 Jan; 12(4):579-583. PubMed ID: 34041490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
